Safety and Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS)-Assisted Weight Loss
NCT ID: NCT03299881
Last Updated: 2021-11-10
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
77 participants
INTERVENTIONAL
2017-09-05
2018-04-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
After signing informed consent, subjects will be screened during a one week screening/baseline period to determine if they meet the inclusion criteria and exhibit none of the exclusion criteria. Weight, blood pressure, blood lipids, HgA1c, pregnancy test (for women of childbearing age), and patient questionnaires will be collected. If eligible, subjects will be randomized to treatment or control groups. The treatment group will receive training on the Elira Wearable Patch System and the first TENS session will be administered in the investigators office. Both groups will receive an electronic scale and instructions on 1200 calorie diet as well as diary completion requirements to be completed throughout the study. All subjects will be required to have in office follow-up visits every 4 weeks for 12 weeks. Up to 2 additional follow-up visits will be permitted within that 12 week time period.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment
The Transcutaneous Nerve Stimulator (TENS) Elira wearable patch system will be applied to varying locations on the T6/T7 dermatone for 30 minutes three times a day after meals. Subjects will be instructed to follow a 1200 calorie healthy diet and record any changes in appetite.
Transcutaneous Nerve Stimulator (TENS)
The Elira wearable patch system is a RF coupled, wearable transcutaneous electrical nerve stimulator (TENS) device controlled via Bluetooth by a smart phone unit running a custom application which directs therapy from the patch within safe limits set by a clinician and also includes a weight loss diary.
Diet & Exercise
Subjects to be instructed on a healthy 1200 calorie diet.
Control
Open label diet and exercise counseling only. Subjects will be instructed to follow a healthy 1200 calorie diet and record any changes in appetite.
Diet & Exercise
Subjects to be instructed on a healthy 1200 calorie diet.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Transcutaneous Nerve Stimulator (TENS)
The Elira wearable patch system is a RF coupled, wearable transcutaneous electrical nerve stimulator (TENS) device controlled via Bluetooth by a smart phone unit running a custom application which directs therapy from the patch within safe limits set by a clinician and also includes a weight loss diary.
Diet & Exercise
Subjects to be instructed on a healthy 1200 calorie diet.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subject has a BMI of 25-35 kg/ m\^2 inclusive.
3. Subject has signed the informed consent form and is able to comply with study protocol and adhere to study visit schedule.
4. Subject is able to wear and use a wearable, patch TENS system.
5. Subject is able to use a touch screen hand held smart phone.
6. Subject is fluent in English and can complete patient questionnaires.
7. Subject can comply with a 1200 calorie the recommended diet for the duration of the study.
8. Subject is male or non-pregnant, non-lactating female, who agrees to use effective contraceptive methods throughout the length of the trial based on PI approval.
9. Females of childbearing potential must have a negative urine pregnancy test at enrollment visit, prior to placement of ELIRA device.
Exclusion Criteria
2. Subject has had a prior bariatric procedure.
3. Subject has any significant multisystem disease in the opinion of the PI.
4. Subject has \> 6.5 HbA1c.
5. Subject has significant cardiac arrhythmia, ectopy, or significant cardiovascular disease.
6. Subject has an existing implanted electrical stimulator (e.g., pacemaker, AICD).
7. Subject is a female of child-bearing potential who is pregnant or intends to become pregnant during the trial.
8. Subject has a history of any malignancy in the last 2 years.
9. Subject has had a weight change of + 5% of his/her Total Body Weight in the 3 months prior to enrollment.
10. Subject has a moderate / severe psychiatric disorder.
11. Subject has a diagnosed neurological disease.
12. Subject has a diagnosed eating disorder.
13. Subject has a skin disorder affecting the thoracic dermatomes.
14. Subject has abdominal surgery or other scars which may interfere with stimulation in the opinion of the PI.
15. Subject is currently enrolled in other, potentially confounding research.
16. Subject has known allergic reaction to materials in the electrodes and/or is otherwise unable to tolerate stimulation with the wearable TENS system.
17. Subject is actively participating or unwilling to discontinue participation in another weight loss program.
18. Subject is taking weight loss control medications including but not limited to OTC medications, Metformin, and Belviq.
19. Subject is unable to take anti-nausea medications planned for the study.
20. Inability to walk at least 0.8 kilometers per day (10 minutes of continuous walking).
21. Current smoker or user of nicotine product or smoking cessation within 1 year of the screening date.
22. History of treatment for or current abuse of drugs or alcohol.
23. A score of ≥10 on the Patient Health Questionnaire 9 (PHQ-9), demonstrating moderate depression.
24. Any subject that the investigator considers inappropriate for the study for medical reasons.
25. Subject has a history of migraine and/or is taking Topiramate for severe headache disorders.
26. Subject is on hormonal or other drug therapy which may alter antral motility or appetite, per physician discretion.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Elira Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shelby Sullivan, MD
Role: PRINCIPAL_INVESTIGATOR
Consultant
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St. Louis Women's Healthcare Group
St Louis, Missouri, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CD-004
Identifier Type: -
Identifier Source: org_study_id